AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01147432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo IV infusion (saline) to be administered during two of the three treatment periods
Trial: NCT04475887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see above
Trial: NCT01549418
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01353209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo given daily for twelve months
Trial: NCT01283009
Drug: Inactive Substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive Substance will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
Trial: NCT02476539
Drug: Hemay022
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00080444
Drug: rescue medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.
Trial: NCT04422678
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care for the Moderate to Severe COVID-19 Pneumonia as per the Egyptian National Protocol by the Ministry of Health.
Trial: NCT02406066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each cohort will have 2 subjects receiving placebo
Trial: NCT00931866
Drug: Diclofenac Sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical diclofenac patch applied once daily to area of pain
Trial: NCT01982539
Drug: Zipsor®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Zipsor® (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treament. Drug taken by mouth.
Trial: NCT03204734
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.
Trial: NCT03204734
Drug: endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: endocrine therapy will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or surgery in the inhibition of ovarian function.
Trial: NCT02822027
Drug: human gamma globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: human gamma globulin for preterm infants with encephalopathy of prematurities
Trial: NCT02822027
Drug: non-human gamma globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-human gamma globulin for preterm infants with encephalopathy of prematurities
Trial: NCT04553380
Drug: basic insulin
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Initial dose of basic insulin: 0.2U/kg/d.~2. Dose titration regimens: the dose is titrated by increments of 0.07U/kg daily until the fasting blood glucose（FBG）≤7 mmol / L, and if the FBG≤ 3.9mmol/L, the 0.07U/kg is reduced.~3. Injection time: subcutaneous injection before going to bed every night.
Trial: NCT02981615
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet a day, from day 10 to day 28 in every cycle of the 4 first cycles
Trial: NCT00796419
Drug: 5% human albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 250 milliliters (mL) 5% human albumin every 8 hours for 5 days
Trial: NCT00796419
Drug: 6% hetastarch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 250mL 6% hetastarch every 8 hours for 5 days
Trial: NCT01694498
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00865410
Drug: Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
Trial: NCT04186637
Drug: ALPN-202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose levels and dose regimens of ALPN-202 will be administered
Trial: NCT02351856
Drug: ARRY-371797, p38 inhibitor, oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, single schedule
Trial: NCT04000854
Drug: Calcium hydroxide (Calacept)
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-term follow up of pulp regenerative treatment using two different root canal dressings: calcium hydroxide and chlorhexidin digluconate in immature necrotic traumatized incisiors
Trial: NCT01509638
Drug: Group 1 Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via PCA pump, as needed.
Trial: NCT00850239
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00701883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules, once a day for 8 weeks
Trial: NCT02378870
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02806206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of a placebo pill will be given to each study participant just before the ingestion of the capsule endoscopy pill.
Trial: NCT00774267
Drug: BZA 20 mg/CE 0.45 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
Trial: NCT00774267
Drug: BZA 20 mg/CE 0.625 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
Trial: NCT00774267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as placebo capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
Trial: NCT03130634
Drug: Silymarin
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
Trial: NCT02282605
Drug: XF-73 nasal gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02282605
Drug: Placebo nasal gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00345748
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectio, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
Trial: NCT03016494
Drug: DWJ1386 Tab.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03948646
Drug: Sofpironium Bromide, 15%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active
Trial: NCT05091775
Drug: Asacol is used to treat and prevent mild to moderate acute fissure disease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of two groups after 2 weeks in fissure wound healing, pain relief, pruritus, burning, bleeding, incontinence. Preliminary results of the study show the rate of fissure improvement 6 weeks after treatment, which is observed by clinical examination. Restoration is defined by complete epithelialization of the fissure site without scarring or residual cracks, and the secondary results will be a reduction in the amount of pain and other symptoms.
Trial: NCT04803396
Drug: DF2755A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DF2755A was planned to be administered in two different parts:~Part A: Single oral dose administration on D1 according to the randomization (50, 150, 300 and 300 mg oad).~Part B: was planned (100 mg bid, 200 mg bid or 300 mg bid) but not performed (repeated oral administration from Day 1 to Day 14).
Trial: NCT03948646
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel
Trial: NCT01205139
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg capsule once daily for 7 days
Trial: NCT01205139
Drug: TMC435 + TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg TMC435 capsule + 300 mg TDF tablet, once daily for 7 days
Trial: NCT01205139
Drug: TMC435 + TMC278
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg TMC435 capsule + 25 mg TMC278 tablet, once daily for 11 days
Trial: NCT01205139
Drug: TMC278
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg tablet once daily for 11 days
Trial: NCT01205139
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg capsule once daily for 11 days
Trial: NCT01823913
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg
Trial: NCT01823913
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of a combination tablet of amlodipine besylate 10mg and valsartan 160mg
Trial: NCT02190604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule- oral dose
Trial: NCT02190604
Drug: QBW251
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule - oral dose
Trial: NCT04409509
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSL312 diluent administered intravenously
Trial: NCT00842491
Drug: endostar, cisplatin, capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Product 1: endostar~Dosing schedule: 15mg daily dose, d1-14~Mode of administration: intravenously
Trial: NCT00842491
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Product 2: capecitabine~Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks~Mode of administration: orally
Trial: NCT01716052
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose
Trial: NCT01716052
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03544762
Drug: 18F-FES PET
RxNorm normalized name: Pet-ema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-FES PET will be performed for each patient. All patients will receive intravenously injection of 5-8 mCi (185-296 MBq) of 18F-FES. PET imaging will be performed on PET/CT system. The 1-frame dynamic data acquisition of thoracic region including the primary tumor will be started immediately after tracer injection. Whole-body PET acquisition from skull base to upper thigh will be started 60 minutes after tracre injection.
Trial: NCT02306902
Drug: ANTARA® (fenofibrate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 130mg, Capsules
Trial: NCT01657240
Drug: PRO-118
FDA approved: no
EMA approved: no
PMDA approved: no
Description: instill one drop in each eye once a day for 21 days
Trial: NCT04338685
Drug: RO7119929
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7119929 will be administered orally as a capsule
Trial: NCT02390869
Drug: R-MANT
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles
Trial: NCT00917904
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage form: vaginal gel~frequency: once daily~duration: 6 weeks
Trial: NCT03339752
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg tablet
Trial: NCT00993941
Drug: Conserved therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral or intravenous administration
Trial: NCT00489658
Drug: Eflornithine plus Nifurtimox combination therapy
RxNorm normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02350296
Drug: KSL 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen lysine salt (KLS) immediate release oral tablets 40 mg, corresponding to 25 mg of ketoprofen free acid. Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design. One (1) tablet of test formulation was administered to the subjects in the morning with 240 mL of still mineral water. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight).
Trial: NCT02350296
Drug: OKi® 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKi® 80 mg granules for oral solution (bipartite sachets: each half sachet containing 40 mg of KLS corresponding to 25 mg of ketoprofen free acid). Ketoprofen lysine salt was administered according to the randomisation list and the cross-over design.~The content of half sachet of the reference formulation was dissolved in 190 mL of still mineral water. The subject drank the entire solution immediately. Then the glass was rinsed with 50 mL of still mineral water and the subject drank the rinse immediately. Afterwards, no fluid intake was permitted for 2 h. All subjects were under fasting conditions from the evening before investigational product administration (i.e. for at least 10 h, overnight).
Trial: NCT00031278
Drug: CPG 7909
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 0.01 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
Trial: NCT00031278
Drug: Herceptin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
Trial: NCT00031278
Drug: CPG 7909
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 0.04 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
Trial: NCT00031278
Drug: CPG 7909
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 0.16 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
Trial: NCT00031278
Drug: CPG 7909
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each 0.32 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
Trial: NCT03426995
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as a matching oral solution or matching capsule to study drug GSK3358699, during Part A and C once daily
Trial: NCT00675272
Drug: hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: hydrocortisone 50mg iv. every 6 hours
Trial: NCT04505592
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo with concomitant heparin to maintain activated partial thromboplastin time between 2.0 and 2.5 upper limit of normal.
Trial: NCT00731302
Drug: aspirin and meloxicam
RxNorm normalized name: bupivacaine and meloxicam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin 81 mg daily then aspirin 81 mg plus meloxicam 7.5 mg daily
Trial: NCT02042807
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02700893
Drug: atropine + atracurium + sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants \< 1000g 0.2 µg/kg for infants \> 1000g
Trial: NCT01699061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet administered with a meal twice a day on Day 1
Trial: NCT02335411
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablets
Trial: NCT02568111
Drug: Vehicle Gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.
Trial: NCT00053911
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00053911
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01338311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mcg twice a day for a total of 7 doses (3.5 days).
Trial: NCT01059435
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously or intravenously
Trial: NCT01765257
Drug: AZILECT®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01765257
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01153334
Drug: Early intensive rosuvastatin therapy (40 mg for 7days, starting in ER prior to primary PCI)
RxNorm normalized name: rosuvastatin 40 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Test group: Early intensive rosuvastatin therapy - rosuvastatin 40 mg for pre-PCI loading and 7 days post PCI and 10 mg daily thereafter 2. Control group: Conventional statin therapy - Placebo for pre-PCI loading in ER and rosuvastatin 10 mg daily after primary PCI
Trial: NCT01134055
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo eye drops
Trial: NCT01437566
Drug: GDC-0941 Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive GDC-0941 matching placebo QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Trial: NCT01437566
Drug: GDC-0980 Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive GDC-0980 matching placebo QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
Trial: NCT03792906
Drug: Norepinephrine 6 mcg
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
Trial: NCT03792906
Drug: Norepinephrine 10 mcg
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
Trial: NCT03792906
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic norepinephrine infusion will be started after subarachnoid block.
Trial: NCT02874989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01967329
Drug: Standard Triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)
Trial: NCT01967329
Drug: Sequential
RxNorm normalized name: TABLET, SEQUENTIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
Trial: NCT01155518
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intramuscular every 2 weeks
Trial: NCT01155518
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intramuscular saline injections every 2 weeks
Trial: NCT01155518
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02566369
Drug: CD5789 (trifarotene) 50μg/g cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD5789 (trifarotene) 50µg/g cream applied once daily for 12 weeks.
Trial: NCT02566369
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream applied once daily for 12 weeks
Trial: NCT00742261
Drug: GSK1363089
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
Trial: NCT00984646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later